Letermovir

Drug Profile

Letermovir

Alternative Names: AIC-001; AIC-090027; AIC-246; BAY-73-6327; MK-8228

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Bayer
  • Developer Merck & Co
  • Class Acetates; Antivirals; Fluorobenzenes; Phenyl ethers; Piperazines; Quinazolines; Small molecules
  • Mechanism of Action Cytomegalovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cytomegalovirus infections

Most Recent Events

  • 01 Nov 2016 Merck Sharp & Dohme completes a phase III trial in Cytomegalovirus Infections (Prevention) in the US, Canada, Peru, Austria, Belgium, France, Finland, Germany, Italy, Lithuania, Poland, Spain, Sweden, Turkey and New Zealand (NCT02137772)
  • 06 Feb 2015 Phase-III clinical trials in Cytomegalovirus infections (Prevention) in Finland, Peru, Turkey and New Zealand (IV)
  • 06 Feb 2015 Phase-III clinical trials in Cytomegalovirus infections (Prevention) in Finland, Peru, Turkey and New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top